Understanding and treating protein damage in porphyria
Mechanism of Proteotoxicity and Experimental Therapeutic Approaches in Porphyria
Trying drugs and lab approaches to stop harmful porphyrin-related protein damage and protect the liver in people with porphyria.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11312573 on NIH RePORTER |
What this research studies
Researchers are focused on how porphyrins cause protein clumping and organ damage even without light, with special attention to the liver where this damage can lead to serious complications. They will use lab-grown cells and animal models to trace the steps that cause porphyrin-driven protein aggregation and to find how cells normally detoxify that damage. The team will screen and characterize small molecules that can lower porphyrin buildup or block its toxic effects, with the goal of identifying candidate therapies. Findings could guide future patient trials and new treatments for people with acute and other porphyrias.
Who could benefit from this research
Good fit: People with acute porphyria (including acute intermittent porphyria) or with porphyrin-related liver disease would be the most relevant candidates for related clinical opportunities.
Not a fit: People without porphyria or those whose organ damage is already irreversible (for example, established end-stage liver disease) are unlikely to benefit directly from these laboratory-focused efforts.
Why it matters
Potential benefit: Could identify drugs that reduce porphyrin accumulation and prevent liver and tissue damage in people with porphyria.
How similar studies have performed: Existing treatments like hemin and RNA-based therapies reduce acute attacks, but directly targeting porphyrin-driven protein aggregation is a newer, mostly preclinical approach.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Omary, Bishr — Rutgers Biomedical and Health Sciences
- Study coordinator: Omary, Bishr
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.